Real-world outcomes were also examined in a small retrospective study of 135 patients with EGFR-mutated advanced NSCLC who received subsequent therapy in 2015 to 2021 after EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.